
    
      Primary Objective:

      The primary objective of this study is to measure the change in ctDNA from trial enrollment
      to after 2 cycles of adjuvant durvalumab in subjects with stage I to III NSCLC who had
      positive ctDNA following definitive treatment with surgery or radiation and completion of
      adjuvant standard of care chemotherapy. Secondary Objectives

        1. To compare disease free survival (DFS)

        2. To compare overall survival (OS)

        3. To evaluate the frequency and severity of toxicity

        4. To evaluate the severity of toxicity
    
  